There was, however, an association with BC risk for all rare, non-synonymous substitutions combined across ATM, CHEK2 and PALB2. This risk could be mediated by a small subset of variants conferring a high risk, or a larger subset of variants associated with a lower risk. Here, PALB2 is linked to breast cancer.